Changes in the stool and oropharyngeal microbiome in obsessive-compulsive disorder

Laura Domènech PhD [1#], Jesse Willis Bsc [1], Maria Alemany BSc [2,3], Marta Morell [1], Eva Real MD, PhD [2,3], Geòrgia Escaramís PhD [1,4], Sara Bertolín MD [3], Daniel Sánchez Chinchilla BSc[1], Susanna Balcells PhD [5,6,7] Cinto Segalàs MD PhD [2,3], Xavier Estivill MD PhD [8], Jose M Menchón MD PhD [2,3, 9,10], Toni Gabaldón PhD [1,11,12], Pino Alonso MD PhD* [3,9,10], Raquel Rabionet PhD* [1,5,6,7]

[1] Bioinformatics and Genomics Programme, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

[2] Institut d' Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain

[3] OCD Clinical and Research Unit, Psychiatry Department, Hospital Universitari de Bellvitge, Barcelona, Spain

[4] CIBERESP (Centro de Investigación en red de Epidemiología y Salud Pública), Instituto de Salud Carlos III, Spain

[5] Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain

[6] CIBERER (Centro de Investigación en red de Enfermedades Raras), Instituto de Salud Carlos III, Spain

[7] Dept. Genetics, Microbiology & Statistics, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Faculty of Biology, University of Barcelona, Barcelona, Spain

[8] Genetics and Genomics Program, Sidra Medical Center, Doha, Qatar

[9] Department of Clinical Sciences, Bellvitge Campus, University of Barcelona, Barcelona, Spain

[10] CIBERSAM (Centro de Investigación en Red de Salud Mental), Instituto de Salud Carlos III, Spain

[11] Universitat Pompeu Fabra (UPF), Barcelona, Spain

[12] Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

[#] current address: Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.

* indicates equal contribution

3   **Corresponding authors:**

4   **Raquel Rabionet:**   Dept. of Genetics, Microbiology and Statistics,

5   Faculty of Biology, University of Barcelona

6   Av. Diagonal 643

7   08028 Barcelona

8   Spain

9   Tel. +34 635 536 508   Email: kelly.rabionet@ub.edu

11 **Pino Alonso:**   OCD Clinical and Research Unit, Department of Psychiatry,

12   Hospital de Bellvitge

13   c/Feixa Llarga s/n

14   Hospitalet de Llobregat

15   08907 Barcelona

16   Spain

17   Tel. +34 93 260 7659   Email: mpalonso@bellvitgehospital.cat

ABSTRACT

Although the etiology of obsessive-compulsive disorder (OCD) is largely unknown, it is accepted that

OCD is a complex disorder. There is a known bi-directional interaction between the gut microbiome and

brain activity. Several authors have reported associations between changes in gut microbiota and

neuropsychiatric disorders, including depression or autism. Furthermore, a pediatric-onset

neuropsychiatric OCD-related syndrome occurs after streptococcal infection, which might indicate that

exposure to certain microbes could be involved in OCD susceptibility. However, only one study has

investigated the microbiome of OCD patients to date. We performed 16S ribosomal RNA gene-based

metagenomic sequencing to analyze the stool and oropharyngeal microbiome composition of 32 OCD

cases and 32 age and gender matched controls. We estimated different α- and β-diversity measures and

performed LEfSe and Wilcoxon tests to assess differences in bacterial distribution. OCD stool samples

showed a trend towards lower bacterial α-diversity, as well as an increase of the relative abundance of

Rikenellaceae, particularly of the genus *Alistipes*, and lower relative abundance of *Prevotellaceae*, and

two genera within the *Lachnospiraceae*: *Agathobacer* and *Coprococcus.* However, we did not observe a

different Bacteroidetes to Firmicutes ratio between OCD cases and controls. Analysis of the

oropharyngeal microbiome composition showed a lower Fusobacteria to Actinobacteria ratio in OCD

cases. In conclusion, we observed an imbalance in the gut and oropharyngeal microbiomes of OCD

cases, including, in stool, an increase of bacteria from the *Rikenellaceae* family, associated with gut

inflammation, and a decrease of bacteria from the *Coprococcus* genus, associated with DOPAC synthesis.

INTRODUCTION

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by intrusive and unwanted thoughts (termed obsessions) and repetitive behaviors or mental acts (called compulsions) that are performed to partially relieve the anxiety or distress caused by the obsessions. The etiology of OCD is largely unknown, although it likely involves a combination of genetic, neurobiological and environmental factors or events. Genetic association studies, including genome-wide association analysis and a multispecies approach integrating evolutionary and regulatory information, have highlighted genes involved in dopamine, serotonin and glutamate signaling, synaptic connectivity and the cortico-striato-thalamo-cortical circuit (CSTC) (Gasso et al., 2015; Mattheisen et al., 2015; Noh et al., 2017; Servaes et al., 2017; Stewart et al., 2013).

Several researchers have speculated that the microbiome might also play a role in the development of OCD (Rees, 2014; Turna et al., 2016). In fact, a recent pilot study of the gut microbiome in OCD has observed some dysbiosis in OCD cases compared to controls (Turna et al., 2020), and a previous work observed a difference in gut microbial composition in deer mice presenting an obsessive behavior compared to the normal individuals (Scheepers et al., 2019), while microbial treatments such as germ-free environment and probiotic treatments can modify OCD-like behavior in rodents (Bastiaanssen et al., 2019), and some OCD risk factors, such as stress, pregnancy or antibiotic use, are known to disrupt the gut microbiome (Rees, 2014). Moreover, it is recognized that some children, after suffering a streptococcal infection, present with a sudden onset of tics, OCD and other behavioral symptoms, a condition known as pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections syndrome (PANS/PANDAS) (Snider and Swedo, 2004).

There is a well-known bi-directional interaction between the gut microbiota and brain activity (Cryan and Dinan, 2012; Mayer et al., 2014). Brain function can be affected by endocrine-, neurocrine- and

inflammation-related signals from the gut microbiota, while psychological and physical stressors can

affect the composition of the gut microbiome (Bailey et al., 2011; Partrick et al., 2018). Differences in

the composition of the gut microbiome have been associated to depression (Valles-Colomer et al.,

2019), autistic disorder (Liu et al., 2019a; Tomova et al., 2015; Vuong and Hsiao, 2017), or schizophrenia

(Schwarz et al., 2018), among other psychiatric disorders. Moreover, two studies have found differences

in gut bacterial distribution when OCD cases or PANS/PANDAS patients are compared to healthy age-

matched individuals (Quagliariello et al., 2018; Turna et al., 2020). On the other hand, some studies have

also shown an alteration of the oropharyngeal microbiome in patients with autism (Hicks et al., 2018;

Qiao et al., 2018) or schizophrenia (Castro-Nallar et al., 2015). However, so far, only one study has

explored a potential link between gut microbiota and OCD, and the OCD oral microbiota has not been

explored yet. Here, we explore the composition of fecal and oropharyngeal microbiota of OCD-patients

before and after treatment and compare it to healthy matched controls.

MATERIAL AND METHODS

Sample collection

Thirty-eight patients (20 females; mean age=40.16±14.12, see Table 1) with a diagnosis of OCD with at

least one year of development were recruited from the OCD clinic at Bellvitge Hospital (Barcelona,

Spain) from January 2016 to September 2017. Diagnoses were assigned by two psychiatrists with

extensive clinical experience in OCD, following the DSM-IV criteria for OCD diagnosis (Association, 1994)

and using the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-I) (First et

al., 1996). A summary of the patients' clinical data is provided in supplementary Table S1. Patients

presenting psychoactive substance abuse/dependence (current or in the past six months), psychotic

disorders, intellectual disability, severe organic or neurological pathology (excepting tic disorder), or

autism spectrum disorder were excluded from the study. Other affective and anxiety disorders were not

criteria for exclusion in cases where OCD was the main diagnosis.

Thirty-three healthy controls (18 females; mean age=36±9.87) were recruited from the same

sociodemographic environment and constituted a comparable sample in terms of age and gender (see

Table 1 and supplementary Table S2 for a summary of clinical information on controls). Prior to

inclusion, each control participant underwent the Structured Clinical Interview for DSM-IV non-patient

version (SCID-NP) (First et al., 2002) to exclude presence or history of any psychiatric disorder.

Written informed consent was obtained from all participants after a complete description of the study,

which was performed in accordance with the Declaration of Helsinki (2013) and approved by Bellvitge

Hospital's ethical committee.

Stool samples from 28 OCD cases at two time-points (before (OCD T0) and after (OCD T3) three months

of pharmacological treatment and cognitive behavioral therapy), 7 OCD cases at a single time-point (4

OCD T0 and 3 OCD T3), and 33 healthy subjects were collected in Stool Collection Tubes (Stratec

Molecular). Samples were stored at -20ºC until processed. DNA was extracted using the PSP Spin Stool

DNA Basic Kit (Stratec Molecular).

Oropharyngeal swab samples, corresponding to the tonsils and the back of the throat, from 28 OCD

cases at two time-points, 8 single timepoint OCD cases (4 OCD T0 and 4 OCD T3) and 32 healthy

individuals were collected with the Catch-All sample collection swabs (Epicentre), conserved in

PowerBead tubes (MO BIO Laboratories), frozen at -20ºC and processed for DNA extraction with the

PowerSoil DNA Isolation kit (MO BIO Laboratories). Details for the overlap between stool T0, stool T3,

oropharyngeal T0 and oropharyngeal T3 samples are provided in Figure S1.

Sample sizes were deemed appropriate for this exploratory approach considering previous similar

studies of microbiota involvement in other psychiatric disorders (Castro-Nallar et al., 2015; Qiao et al.,

2018; Quagliariello et al., 2018; Schwarz et al., 2018; Tomova et al., 2015; Turna et al., 2020), performed

with similar sample sizes.

All participants were asked to provide dietary information through a questionnaire (supplementary

tables S3 and S4). Severity of the obsessive and compulsive symptoms before and after treatment

among the OCD patients was assessed through the clinician-administered version of the Yale-Brown

Obsessive Compulsive Scale (Y-BOCS) (Goodman et al., 1989). A global measure as well as independent

ones for both obsessions and compulsions were taken. Table 1 and supplementary Tables S1 and S2

summarize the main characteristics of the OCD and control cohorts.

Sequencing and data analysis

16S ribosomal RNA (rRNA) sequencing was performed by the UPF Genomics Core Facility following

Illumina's protocol with slight modifications. Briefly, in each sample, the variable V3-V4 region of the 16S

rRNA gene was amplified for 35 cycles using the primers described in Klindworth et al. (Klindworth et al.,

2013) and Platinum High Fidelity Taq (Thermofisher) and purified, followed by 8 cycles of indexing PCR,

and quantification. The indexed products were then pooled in an equimolar way in two final amplicon

libraries (one for stool and one for tonsils), each containing 96 samples. Each library was sequenced in

one 2 x 300 bp paired-end sequencing run on a MiSeq System.

The DADA2 R package (version 1.6.0) (Callahan et al., 2016) was employed to obtain counts of amplicon

sequence variants (ASV), and sequence taxonomy was assigned using the SILVA database (Yilmaz et al.,

2014). Resulting ASV counts, along with clinical data and diet information collected for each individual,

were stored and analyzed using the Phyloseq package (version 1.22.3). 16S counts were normalized per

sample, obtaining the relative abundance of each taxon within a sample, with all values ranging

between 0 and 100.

We estimated different α- (within samples) and β-diversity (between samples) measures using the

Phyloseq, picante and vegan R packages (see supplementary material for details). α-diversity indices

1 included the Shannon and Simpson Diversity Index, Faith's phylogenetic diversity, the observed species

2 index, the Chao1 index and the ACE (Abundance-based Coverage Estimator) index. β-diversity measures

3 included Unifrac distances, the Bray-Curtis dissimilarity, Jensen-Shannon diversity and Canberra indices.

4 We performed a PERMANOVA test on β-diversity with 999 permutations considering even dependence

5 of samples (paired OCD samples after and before treatment). Finally, we applied a Principal Coordinate

6 Analysis (PCoA) to visualize the clustering of the samples.

7 **Statistical analysis**

8 Correlation between categorical variables (i.e. sample type, type of obsessions, etc.) and taxa

9 abundances or other continuous variables was tested using the Kruskal-Wallis rank sum test, and

10 correlation between two categorical variables was tested using Chi-squared tests. Statistical significance

11 of α-diversity differences between groups was evaluated with Mann–Whitney U test when samples

12 were independent, and with Wilcoxon rank-sum test when samples were paired. In all cases, we applied

13 the Bonferroni correction to adjust the p-values by the number of comparisons and provide only

14 corrected p-values. Correlation plots and boxplots were generated using *ggplot2* (version 2.2.1) and

15 association plots were generated using the *assoc* function from the R package *vcd* (version 1.4.4).

16 Linear discriminant analysis Effect Size (LEfSe) was performed using the Huttenhower lab's tool

17 implemented in Galaxy web (Segata et al., 2011). For the statistical test we used an α value of 0.05 and a

18 logarithmic LDA score threshold of 2.0.

RESULTS

High-throughput sequencing analysis of bacterial 16S rRNA V3–V4 regions was conducted on fecal and oropharyngeal samples of the 32 OCD (two timepoints) and 33 control individuals (see Figure S1). In total, 8,653,960 high-quality reads (90,145.42 ± 15,356.44 reads/sample) were obtained from all 96 fecal samples, representing 196 operational taxonomic units (OTUs) when considering all samples, while each sample had, on average, 91.77 ± 17.51 OTUs. For the 96 oropharyngeal samples, 6,051,021 high-quality reads (63,031.47 ± 16555 reads/sample) were obtained, representing 81 operational taxonomic units for all samples, with an average of 32.22 ± 9.29 OTUs/sample.

While statistical analyses revealed some differences between cases (at T0 and/or at T3) and controls, no statistically significant differences were identified when comparing OCD cases before and after treatment (T0 vs T3).   On the other hand, we observed some association between some of the diet variables and taxa abundances, but there were no significant associations between the variables collected in the diet questionnaires and whether the individual belonged to the OCD or control group, which suggests that the taxa differences between OCD cases and controls may be influenced by the OCD phenotype, rather than by other variables.

OCD samples show a trend towards lower bacterial α- diversity in the gut

Analysis of the microbial composition of the gut showed that OCD T0 samples presented an overall lower level of all α-diversity indices compared to the control group, although no test reached statistical significance after adjusting for multiple testing (Bonferroni adjusted p-value = 0.057) (Figure 1A). These differences were reduced in the OCD T3 group. On the other hand, we did not observe a strong separation of sample groups based on the β-diversity measures (Figure S2), and there were no statistical differences between the Bacteroidetes to Firmicutes ratio when comparing OCD samples to controls (Wilcoxon rank-sum test Bonferroni adjusted p-value = 0.0653; Figure 2A). In all three groups, the 20

most abundant genera belonged to either the Bacteroidetes or Firmicutes Phyla, while at the family

level there was also representation of *Proteobacteria*, *Verrucomicrobia* and *Actinobacteria*, albeit at very

low abundances (Figure S3).

LEfSe results reveal an enrichment for *Rikenellaceae* and depletion of *Prevotellaceae,* and a shift from

***Coprococcus* to *Flavonifractor* within the Clostridiales in the gut**

LEfSe analysis revealed a significant increase of the relative abundance of *Rikenellaceae*, particularly of

the *Alistipes* genus, and a decrease in the levels of *Prevotellaceae,* in OCD T0 stool samples compared to

controls (Figure 3). We also observed a different distribution of bacteria from the order Clostridiales,

where OCD T0 samples presented a higher abundance of the genera *Oscillibacter, Anaerostipes* and

Flavonifractor, and a depletion of *Agathobacter, Coprococcus, Lachnospira, Howardella, Romboutsia,*

Butyricicoccus and *Clostridium* compared to controls. In addition, within these, depletion of *Lachnospira*

pectinoschiza correlated with OCD severity on the obsessions subscale (YBOCS_OBS_0 vs Species

Lachnospira pectinoschiza r =-0.420). Relative abundances in stool samples from cases and controls for

these taxa are presented in Table S5. Most of these differences are also present when comparing OCD

post-treatment samples versus controls (Figure S4).

In the oropharyngeal microbiome, OCD samples show a lower Fusobacteria to Actinobacteria ratio

Again, in the analysis of the oropharyngeal microbiome, α-diversity indices did not show significant

differences between the OCD and control groups (Figure 1B). Similarly, we did not see any separation of

sample groups based on most β-diversity measures (Figure S5). However, there was a significant

difference in the ratio of Fusobacteria to Actinobacteria when comparing OCD samples (T0 and T3) to

controls (Wilcoxon rank-sum test p-value = 0.004; c, Figure 2B), where OCD samples had lower ratios.

Bacterial diversity in the oropharyngeal samples was lower than in the stool samples (Shannon diversity:

Stool= 3.17 ± 0.46, oropharyngeal= 2.46 ± 0.45; Faiths PD: Stool= 23.18 ± 4.00, oropharyngeal= 15.25 ±

4.53). Among the 20 most abundant genera, the largest contribution belonged to the Actinobacteria and

Fusobacteria phyla, although Epsilonbacteraeota (e.g. *Campylobacter),* Bacteroidetes, Firmicutes and

Proteobacteria were also represented (Figure S6).

LEfSe analysis of the oropharyngeal microbiome data revealed an increase of species within the

Actinobacteria and Coriobacteriia classes in the OCD samples: particularly, the genera *Actinomyces* and

Atopobium represented a higher percentage of total bacteria in OCD T0 compared to control samples;

there was also an increase of *Lachnospiraceae* and other Firmicutes. In contrast, control samples had a

higher percentage of bacteria from the Fusobacteriia class (Figure 4). Analysis of OCD T3 vs controls

highlighted again the increase of the Actinobacteria and Coriobacteriia (Figure S7). Relative abundances

in oropharyngeal samples from cases and controls for these taxa are presented in Table S6.

We also performed a directed analysis of enrichment of *Streptococcus* in OCD samples versus controls,

as this genus has been shown to be associated to the onset of PANDAS (Quagliariello et al., 2018).

However, the top 15 most abundant species did not include bacteria form this genus in either OCD T0,

OCD T3, or controls.

DISCUSSION

We have performed an explorative comparative analysis of the gut (fecal) and oropharyngeal

microbiome between OCD cases (before and after treatment) and age- and gender-matched healthy

controls, via 16S rRNA amplicon sequencing.

While our analysis shows only a trend towards lower bacterial diversity in the gut of OCD patients which

is not significant after correction for multiple testing, this result is consistent with the lower gut α-

diversity in PANS/PANDAS patients reported by Quagliariello et al. (2018), and in OCD by Turna et al.

(2020). Lower α-diversity has also been reported in subjects with attention deficit hyperactivity disorder

(Prehn-Kristensen et al., 2018), and in some studies of ASD individuals (Kang et al., 2018; Kang et al.,

2013; Liu et al., 2019b), although it is not consistenly observed, and may be dependent on the cohort

characteristics, including sample size. Nevertheless, most of these studies, as ours, are exploratory

analyses with small sample sizes, which may explain differences in the specific indexes reported

significant. In addition, in the analysis of Quagliariello et al. (2018) they also observed, in the younger

subset of PANS/PANDAS patients (aged 4-8 years), a higher percentage of Bacteroidetes and lower level

of Firmicutes, while we did not observe significant shifts in the Bacteroidetes to Firmicutes ratio. This

discrepancy between our results and those of Quagliariello et al. (2018) could be related to the age of

our subjects, as all our patients are adults, while their study was performed on pediatric cases. However,

we did not observe a correlation between age and any of the taxa ratios tested. Additional analyses on

larger cohorts should clarify the observed trends.

The Wilcoxon and LEfSe tests performed here highlighted differences in OTU abundances in the gut:

interestingly, we observed an increase of bacteria from the *Rikenellaceae* family, which had been

reported as a biomarker of PANDAS (Quagliariello et al., 2018). In addition, an increase in abundance of

Rikenellaceae has also been reported in ADHD (Aarts et al., 2017) and major depressive disorder (MDD)

(Jiang et al., 2015). This bacterial family and, specifically, the *Alistipes* genus, is also positively associated

with gut inflammation in human and mice studies (Bassett et al., 2015; Saulnier et al., 2011). Recently, a

study linked neuroinflammation throughout the CSTC circuit to OCD (Attwells et al., 2017). Considering

these observations, it is tempting to speculate a possible link between the neuroinflammation observed

in OCD patients and the higher abundance o*f Alistipes and Rikenellaceae* in these patients. Finally, OCD

T0 samples showed lower levels of bacteria of the *Prevotellaceae* family, similarly to reports on ASD (Liu

et al., 2019b).

LEfSe analysis also found specific members of the Firmicutes phylum with higher abundance in OCD T0

samples: *Oscillibacter*, *Anaerostipes*, and *Flavonifractor,* and a lower abundance *of Coprococcus and*

Lachnospira; futhermore, abundance of *Lachnospira pectinoschi*za was also negatively correlated with

severity, in line with the depletion in cases compared to controls. While several of these differences are

maintained when comparing OCD post-treatment samples to the control group, the decrease in the

genus *Lachnospira* is not. Furthermore, Valles-Colomer et al. (2019) report a correlation of four mental

well-being scores (measured by the RAND-36 health-related quality of life survey) with higher

abundance of *Coprococcus,* and two of these (social functioning and emotional well-being) also correlate

with a lower abundance of *Flavonifractor* genus in the gut microbiota. We observe precisely the

opposite trend in our cohort of OCD patients, where OCD patients have lower abundance of

Coprococcus and higher abundance of *Flavonifractor*. The relative abundance of *Coprococcus* in the

aforementioned study was strongly associated with the microbial pathway for DOPAC (a dopamine

metabolite) synthesis. Relevantly, dopaminergic transmission has been implicated in the neurobiology of

OCD, as dopamine receptor agonists are effective as an augmentation therapy to selective serotonin

reuptake inhibitors in reducing OC symptoms (Vulink et al., 2009), and OCD patients under deep brain

stimulation show improvements associated with release of striatal dopamine (Figee et al., 2014) .

However, our results are not replicating the findings by Turna et al. (2020). In their study, they observed

a lower relative abundance of *Oscillospira*, *Odoribacter* and *Anaerostipes*. We do not see a significant

difference for *Oscillospira* and *Odoribacter*, although a detailed look at the data show that, for

Oscillospira, a similar trend is present, with lower abundance in OCD T0 samples compared to controls,

and an increase in abundance in OCD T3 samples (supplementary table s5, figure S8). On the other hand,

in the case of *Anaerostipes* we observe an increase of these bacteria as opposed to what was previously

reported. These differences might be explained by chance, as both studies have a small, exploratory,

sample size, or it could be related to dietary differences or to methodological differences in the analysis

between both studies.

We also analyzed the oropharyngeal microbiome of OCD cases and controls. While the composition of

the oral microbiome has received little attention in relation with psychiatric diseases, there are some studies that indicate possible changes in the oral microbiota of Parkinson's disease or autistic disorder (Clarke et al., 1998; Hicks et al., 2018; Mihaila et al., 2019). In addition, the bacterial composition of the oral cavity might be used to represent the composition of the upper gastrointestinal tract (Tsuda et al., 2015). Furthermore, in this case we were particularly interested in the evaluation of the presence of *Streptococcus pyogenes*, as a potential biomarker of OCD, as it had been associated with PANDAS (Orefici et al., 2016), but we did not detect this species in our dataset. We then analyzed bacterial diversity measures between cases and controls without observing an overall difference in α-diversity. We did observe a significantly higher Actinobacteria to Fusobacteria ratio in OCD T0 compared to controls, which is still present, but reduced, after treatment. This difference correlated with an increase in *Actinomycetales* and a decrease of *Fusobacteriales* observed in the LEfSe analysis. We then analyzed whether the Fusobacteria to Actinobacteria ratio could be used as a proxy for the increased abundance of *Alistipes* and *Rikenellaceae* in the gut microbiome, but we did not detect a significant correlation with either *Alistipes* or *Rikenellaceae*. The Fusobacteria/Actinobacteria ratio was, however, correlated with the presence of the *Coprococcus* genus or the *Eggerthellaceae* family (Figure S9).

While our results support an imbalance in OCD cases, both in the gut and the oropharyngeal microbiome, it is not possible to establish a causal relationship, as the observed changes in the microbiome can be both a cause or a consequence of the disorder. It has been shown that the brain can modulate the gut microbiome by a top-down function of the gut-brain axis. For instance, the lower α-diversity observed in OCD cases could be a consequence of the anxiety provoked by obsessions. Since our study included only patients already diagnosed with OCD, it is not possible to discern between cause and effect. Further studies involving animal models, larger sample sizes, longitudinal cohorts and eventually, interventional experiments, should help understand the contribution of intestinal and oral

microbiota to obsessive-compulsive disorder. In this regard, a recent animal study points toward the

existence of an underlying aetiological association between alterations in gut microbiota and

development of obsessive-compulsive behavior (Scheepers et al., 2019). Our analysis has some

limitations: the study sample size is relatively small, although in line with other exploratory studies in

autism or depression; on the other hand, gut microbiome composition has been analyzed through the

bacterial composition of stool samples, which represents mostly the composition of the colon, while

underestimating that of other regions of the gut such as the small intestine. Nevertheless, most

studies on the gut microbiome use this same sample source, as it is more accessible and less

invasive.

In summary, our results and those of others indicate that the gut microbiome might be playing a role in

the pathogenesis of OCD, which might involve an increase in inflammation levels related to

overabundance of bacteria in the *Alistipes* genus, or be related to a decrease in abundance of *Prevotella*

and *Coprococcus* genera, the latter associated with the microbial DOPAC synthesis pathway. While

awaiting confirmation on additional cohorts, these results open the door to further explorations into

possible interventions directed to the modulation of both the microbiota in OCD patients or the

mechanisms through which they exert their effect.

ACKNOWLEDGEMENTS

This project was supported by grants from the Spanish ministry of science and innovation (MICINN;

SAF2013-49108-R); the Carlos III Health Institute (PI16/00950 PI18/00856); FEDER funds ('A way to build

Europe') and by the Agency of University and Research Funding Management of the Catalan

Government (2014SGR1672). LD was supported by a Severo Ochoa grant (SVP-2013-068066), MA was

supported by the Secretariat for Universities and Research of the Ministry of Business and Knowledge of

the Government of Catalonia Grant co-funded by the European Social Fund (ESF) "ESF, Investing in your

future" (2017 FI_B 00327), DSC was supported by a grant from the MICINN (BES-2014-069814) and RR

was supported by a fellowship from the Health Department of the Generalitat de Catalunya through the

PERIS 2016-2020 program (SLT002/16/).

REFERENCES

Aarts, E., Ederveen, T.H.A., Naaijen, J., Zwiers, M.P., Boekhorst, J., Timmerman, H.M., Smeekens,

S.P., Netea, M.G., Buitelaar, J.K., Franke, B., van Hijum, S., Arias Vasquez, A., 2017. Gut microbiome in

ADHD and its relation to neural reward anticipation. PLoS One 12, e0183509.

Association, A.P., 1994. DSM-IV-TR : Diagnostic and Statistical Manual of Mental Disorders, 4th Ed.

American Psychiatric Press, Washington, DC.

Attwells, S., Setiawan, E., Wilson, A.A., Rusjan, P.M., Mizrahi, R., Miler, L., Xu, C., Richter, M.A., Kahn,

A., Kish, S.J., Houle, S., Ravindran, L., Meyer, J.H., 2017. Inflammation in the Neurocircuitry of Obsessive-

Compulsive Disorder. JAMA Psychiatry 74, 833-840.

Bailey, M.T., Dowd, S.E., Galley, J.D., Hufnagle, A.R., Allen, R.G., Lyte, M., 2011. Exposure to a social

stressor alters the structure of the intestinal microbiota: implications for stressor-induced

immunomodulation. Brain Behav Immun 25, 397-407.

Bassett, S.A., Young, W., Barnett, M.P., Cookson, A.L., McNabb, W.C., Roy, N.C., 2015. Changes in

composition of caecal microbiota associated with increased colon inflammation in interleukin-10 gene-

deficient mice inoculated with Enterococcus species. Nutrients 7, 1798-1816.

Bastiaanssen, T.F.S., Cowan, C.S.M., Claesson, M.J., Dinan, T.G., Cryan, J.F., 2019. Making Sense of ...

the Microbiome in Psychiatry. Int J Neuropsychopharmacol 22, 37-52.

Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J., Holmes, S.P., 2016. DADA2:

High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581-583.

Castro-Nallar, E., Bendall, M.L., Perez-Losada, M., Sabuncyan, S., Severance, E.G., Dickerson, F.B.,

Schroeder, J.R., Yolken, R.H., Crandall, K.A., 2015. Composition, taxonomy and functional diversity of the

oropharynx microbiome in individuals with schizophrenia and controls. PeerJ 3, e1140.

Clarke, R., Smith, A.D., Jobst, K.A., Refsum, H., Sutton, L., Ueland, P.M., 1998. Folate, vitamin B12,

and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 55, 1449-1455.

Cryan, J.F., Dinan, T.G., 2012. Mind-altering microorganisms: the impact of the gut microbiota on

brain and behaviour. Nature Reviews Neuroscience 13, 701.

Figee, M., de Koning, P., Klaassen, S., Vulink, N., Mantione, M., van den Munckhof, P., Schuurman,

R., van Wingen, G., van Amelsvoort, T., Booij, J., Denys, D., 2014. Deep brain stimulation induces striatal

dopamine release in obsessive-compulsive disorder. Biol Psychiatry 75, 647-652.

First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1996. Structured Clinical Interview for DSM-IV

Axis I Disorders-Clinician Version (SCID-CV). American Psychiatric Press, Washington, DC.

First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 2002. StructuredClinical Interview for DSM-IV-

TR Axis I Disorders, Research Version, Non-Patient Edition. (SCID-I/NP), New York: Biometrics Research.

New York State Psychiatric Institute.

Gasso, P., Ortiz, A.E., Mas, S., Morer, A., Calvo, A., Bargallo, N., Lafuente, A., Lazaro, L., 2015.

Association between genetic variants related to glutamatergic, dopaminergic and neurodevelopment

pathways and white matter microstructure in child and adolescent patients with obsessive-compulsive

disorder. J Affect Disord 186, 284-292.

Goodman, W.K., Price, L.H., Rasmussen, S.A., Mazure, C., Fleischmann, R.L., Hill, C.L., Heninger, G.R.,

Charney, D.S., 1989. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Arch Gen Psychiatry 46, 1006-1011.

Hicks, S.D., Uhlig, R., Afshari, P., Williams, J., Chroneos, M., Tierney-Aves, C., Wagner, K., Middleton,

F.A., 2018. Oral microbiome activity in children with autism spectrum disorder. Autism research : official

journal of the International Society for Autism Research 11, 1286-1299.

Jiang, H., Ling, Z., Zhang, Y., Mao, H., Ma, Z., Yin, Y., Wang, W., Tang, W., Tan, Z., Shi, J., Li, L., Ruan,

B., 2015. Altered fecal microbiota composition in patients with major depressive disorder. Brain Behav

Immun 48, 186-194.

Kang, D.W., Ilhan, Z.E., Isern, N.G., Hoyt, D.W., Howsmon, D.P., Shaffer, M., Lozupone, C.A., Hahn, J.,

Adams, J.B., Krajmalnik-Brown, R., 2018. Differences in fecal microbial metabolites and microbiota of

children with autism spectrum disorders. Anaerobe 49, 121-131.

Kang, D.W., Park, J.G., Ilhan, Z.E., Wallstrom, G., Labaer, J., Adams, J.B., Krajmalnik-Brown, R., 2013.

Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS

One 8, e68322.

Klindworth, A., Pruesse, E., Schweer, T., Peplies, J., Quast, C., Horn, M., Glockner, F.O., 2013.

Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation

sequencing-based diversity studies. Nucleic Acids Res 41, e1.

Liu, F., Li, J., Wu, F., Zheng, H., Peng, Q., Zhou, H., 2019a. Altered composition and function of

intestinal microbiota in autism spectrum disorders: a systematic review. Translational Psychiatry 9, 43.

Liu, S., Li, E., Sun, Z., Fu, D., Duan, G., Jiang, M., Yu, Y., Mei, L., Yang, P., Tang, Y., Zheng, P., 2019b.

Altered gut microbiota and short chain fatty acids in Chinese children with autism spectrum disorder. Sci

Rep 9, 287.

Mattheisen, M., Samuels, J.F., Wang, Y., Greenberg, B.D., Fyer, A.J., McCracken, J.T., Geller, D.A.,

Murphy, D.L., Knowles, J.A., Grados, M.A., Riddle, M.A., Rasmussen, S.A., McLaughlin, N.C., Nurmi, E.L.,

Askland, K.D., Qin, H.D., Cullen, B.A., Piacentini, J., Pauls, D.L., Bienvenu, O.J., Stewart, S.E., Liang, K.Y.,

Goes, F.S., Maher, B., Pulver, A.E., Shugart, Y.Y., Valle, D., Lange, C., Nestadt, G., 2015. Genome-wide

association study in obsessive-compulsive disorder: results from the OCGAS. Mol Psychiatry 20, 337-344.

Mayer, E.A., Knight, R., Mazmanian, S.K., Cryan, J.F., Tillisch, K., 2014. Gut microbes and the brain:

paradigm shift in neuroscience. J Neurosci 34, 15490-15496.

Mihaila, D., Donegan, J., Barns, S., LaRocca, D., Du, Q., Zheng, D., Vidal, M., Neville, C., Uhlig, R.,

Middleton, F.A., 2019. The oral microbiome of early stage Parkinson's disease and its relationship with

functional measures of motor and non-motor function. PLoS One 14, e0218252.

Noh, H.J., Tang, R., Flannick, J., O'Dushlaine, C., Swofford, R., Howrigan, D., Genereux, D.P., Johnson,

J., van Grootheest, G., Grunblatt, E., Andersson, E., Djurfeldt, D.R., Patel, P.D., Koltookian, M., C, M.H.,

Pato, M.T., Pato, C.N., Rasmussen, S.A., Jenike, M.A., Hanna, G.L., Stewart, S.E., Knowles, J.A.,

Ruhrmann, S., Grabe, H.J., Wagner, M., Ruck, C., Mathews, C.A., Walitza, S., Cath, D.C., Feng, G.,

Karlsson, E.K., Lindblad-Toh, K., 2017. Integrating evolutionary and regulatory information with a

multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nat Commun 8,

774.

Orefici, G., Cardona, F., Cox, C.J., Cunningham, M.W., 2016. Pediatric autoimmune neuropsychiatric

disorders associated with streptococcal infections (PANDAS), in: J., F.J., L., S.D., A., F.V. (Eds.),

Streptococcus pyogenes: Basic Biology to Clinical Manifestations. University of Oklahoma Health

Sciences Center, Oklahoma city, OK.

Partrick, K.A., Chassaing, B., Beach, L.Q., McCann, K.E., Gewirtz, A.T., Huhman, K.L., 2018. Acute and

repeated exposure to social stress reduces gut microbiota diversity in Syrian hamsters. Behav Brain Res

345, 39-48.

Prehn-Kristensen, A., Zimmermann, A., Tittmann, L., Lieb, W., Schreiber, S., Baving, L., Fischer, A.,

2018. Reduced microbiome alpha diversity in young patients with ADHD. PLoS One 13, e0200728.

Qiao, Y., Wu, M., Feng, Y., Zhou, Z., Chen, L., Chen, F., 2018. Alterations of oral microbiota distinguish

children with autism spectrum disorders from healthy controls. Sci Rep 8, 1597.

Quagliariello, A., Del Chierico, F., Russo, A., Reddel, S., Conte, G., Lopetuso, L.R., Ianiro, G.,

Dallapiccola, B., Cardona, F., Gasbarrini, A., Putignani, L., 2018. Gut Microbiota Profiling and Gut-Brain

Crosstalk in Children Affected by Pediatric Acute-Onset Neuropsychiatric Syndrome and Pediatric

Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. Front Microbiol 9,

675.

Rees, J.C., 2014. Obsessive-compulsive disorder and gut microbiota dysregulation. Med Hypotheses

82, 163-166.

Saulnier, D.M., Riehle, K., Mistretta, T.A., Diaz, M.A., Mandal, D., Raza, S., Weidler, E.M., Qin, X.,

Coarfa, C., Milosavljevic, A., Petrosino, J.F., Highlander, S., Gibbs, R., Lynch, S.V., Shulman, R.J.,

Versalovic, J., 2011. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel

syndrome. Gastroenterology 141, 1782-1791.

Scheepers, I.M., Cryan, J.F., Bastiaanssen, T.F.S., Rea, K., Clarke, G., Jaspan, H.B., Harvey, B.H.,

Hemmings, S.M.J., Santana, L., van der Sluis, R., Malan-Muller, S., Wolmarans, W., 2019. Natural

compulsive-like behaviour in the deer mouse (Peromyscus maniculatus bairdii) is associated with altered

gut microbiota composition. Eur J Neurosci.

Schwarz, E., Maukonen, J., Hyytiainen, T., Kieseppa, T., Oresic, M., Sabunciyan, S., Mantere, O.,

Saarela, M., Yolken, R., Suvisaari, J., 2018. Analysis of microbiota in first episode psychosis identifies

preliminary associations with symptom severity and treatment response. Schizophr Res 192, 398-403.

Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W.S., Huttenhower, C., 2011.

Metagenomic biomarker discovery and explanation. Genome Biol 12, R60.

Servaes, S., Glorie, D., Verhaeghe, J., Stroobants, S., Staelens, S., 2017. Preclinical molecular imaging of glutamatergic and dopaminergic neuroreceptor kinetics in obsessive compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 77, 90-98.

Snider, L.A., Swedo, S.E., 2004. PANDAS: current status and directions for research. Mol Psychiatry 9, 900-907.

Stewart, S.E., Yu, D., Scharf, J.M., Neale, B.M., Fagerness, J.A., Mathews, C.A., Arnold, P.D., Evans, P.D., Gamazon, E.R., Davis, L.K., Osiecki, L., McGrath, L., Haddad, S., Crane, J., Hezel, D., Illman, C., Mayerfeld, C., Konkashbaev, A., Liu, C., Pluzhnikov, A., Tikhomirov, A., Edlund, C.K., Rauch, S.L., Moessner, R., Falkai, P., Maier, W., Ruhrmann, S., Grabe, H.J., Lennertz, L., Wagner, M., Bellodi, L., Cavallini, M.C., Richter, M.A., Cook, E.H., Jr., Kennedy, J.L., Rosenberg, D., Stein, D.J., Hemmings, S.M., Lochner, C., Azzam, A., Chavira, D.A., Fournier, E., Garrido, H., Sheppard, B., Umana, P., Murphy, D.L., Wendland, J.R., Veenstra-VanderWeele, J., Denys, D., Blom, R., Deforce, D., Van Nieuwerburgh, F., Westenberg, H.G., Walitza, S., Egberts, K., Renner, T., Miguel, E.C., Cappi, C., Hounie, A.G., Conceicao do Rosario, M., Sampaio, A.S., Vallada, H., Nicolini, H., Lanzagorta, N., Camarena, B., Delorme, R., Leboyer, M., Pato, C.N., Pato, M.T., Voyiaziakis, E., Heutink, P., Cath, D.C., Posthuma, D., Smit, J.H., Samuels, J., Bienvenu, O.J., Cullen, B., Fyer, A.J., Grados, M.A., Greenberg, B.D., McCracken, J.T., Riddle, M.A., Wang, Y., Coric, V., Leckman, J.F., Bloch, M., Pittenger, C., Eapen, V., Black, D.W., Ophoff, R.A., Strengman, E., Cusi, D., Turiel, M., Frau, F., Macciardi, F., Gibbs, J.R., Cookson, M.R., Singleton, A., North American Brain Expression, C., Hardy, J., Database, U.K.B.E., Crenshaw, A.T., Parkin, M.A., Mirel, D.B., Conti, D.V., Purcell, S., Nestadt, G., Hanna, G.L., Jenike, M.A., Knowles, J.A., Cox, N., Pauls, D.L., 2013. Genome-wide association study of obsessive-compulsive disorder. Mol Psychiatry 18, 788-798.

Tomova, A., Husarova, V., Lakatosova, S., Bakos, J., Vlkova, B., Babinska, K., Ostatnikova, D., 2015. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav 138, 179-187.

Tsuda, A., Suda, W., Morita, H., Takanashi, K., Takagi, A., Koga, Y., Hattori, M., 2015. Influence of

Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. Clin Transl

Gastroenterol 6, e89.

Turna, J., Grosman Kaplan, K., Anglin, R., Patterson, B., Soreni, N., Bercik, P., Surette, M.G., Van

Ameringen, M., 2020. The gut microbiome and inflammation in Obsessive-Compulsive Disorder patients

compared to age- and sex-matched controls: a pilot study. Acta Psychiatr Scand.

Turna, J., Grosman Kaplan, K., Anglin, R., Van Ameringen, M., 2016. "What's Bugging the Gut in

Ocd?" a Review of the Gut Microbiome in Obsessive-Compulsive Disorder. Depress Anxiety 33, 171-178.

Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E.F., Wang, J., Tito, R.Y., Schiweck, C.,

Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S.,

Raes, J., 2019. The neuroactive potential of the human gut microbiota in quality of life and depression.

Nat Microbiol.

Vulink, N.C., Denys, D., Fluitman, S.B., Meinardi, J.C., Westenberg, H.G., 2009. Quetiapine augments

the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind,

placebo-controlled study of 76 patients. J Clin Psychiatry 70, 1001-1008.

Vuong, H.E., Hsiao, E.Y., 2017. Emerging Roles for the Gut Microbiome in Autism Spectrum Disorder.

Biol Psychiatry 81, 411-423.

Yilmaz, P., Parfrey, L.W., Yarza, P., Gerken, J., Pruesse, E., Quast, C., Schweer, T., Peplies, J., Ludwig,

W., Glockner, F.O., 2014. The SILVA and "All-species Living Tree Project (LTP)" taxonomic frameworks.

Nucleic Acids Res 42, D643-648.

TABLES

Table 1. Age and gender characteristics for the control and OCD sample cohorts.

Group	Female	Male	Age Aver (SD; range)	Diet					
				Q6	Q7	Q11	Q12	Q17	Q18
OCD	20	18	40.16 (14.12;18-71)	1.5	2.4	3.1	2.2	2.1	2.5
Control	18	15	36.00 (9.87; 23-59)	2.15	2.4	3.6	2.1	2.1	2.5

Female/Male: number of female/male participants; Aver: average; SD: standard deviation; Diet: average value for group responses to questionnaire questions Q6 (alcohol); Q7 (yoghurt, kefir…); Q11 (vegetables); Q12 (beans); Q17 (red meat) and Q18 (white meat); values range from 1 (not in last 7 days) to 4 (daily). For more details, see questionnaire in supplementary table S3.

FIGURES

Figure 1. Boxplots representing α-diversity indices: Observed, Chao1, ACE, Shannon, Simpson, Inverted Simpson, Fisher and PD. The plots represent the median, 25th, and 75th percentiles calculated for Controls (red), OCD T0 (green) and OCD T3 (blue) in stool samples (**a**) or oropharyngeal samples (**b**). The corresponding Bonferroni adjusted p-values are reported below each index (OCD T0 vs controls and OCD T3 vs controls was calculated with Mann–Whitney U test; OCD T0 vs 0CD T3 with Wilcoxon rank-sum test).

A

B

Figure 2. Notched boxplots representing the values of the ratio for the two most abundant taxa in each area: **a**. Firmicutes to Bacteroidetes ratio in gut samples from Control, OCD T0 and OCD T3 subjects. **b**. Fusobacteria to Actinobacteria ratio in Oropharyngeal samples from Control, OCD T0 and OCD T3 subjects. Bonferroni adjusted p-value of Wilcoxon rank-sum test between Controls and OCD T0, and controls and OCD T3 are indicated.

A

B

Figure 3.a. Biomarkers associated with OCD and control groups discovered by LEfSe analysis (α value=0.05, logarithmic LDA score threshold=2.0) in stool samples. **b**. Cladogram representing the phylogenetic relationship of biomarkers associated with OCD and control groups through the Linear discriminant Effect Size (LEfSe) analysis (α value=0.05, logarithmic LDA score threshold=2.0) in stool samples.

Figure 4. **a**. Biomarkers associated with OCD and control groups discovered by LEfSe analysis (α value=0.05, logarithmic LDA score threshold=2.0) in oropharyngeal samples. **b**. Cladogram representing the phylogenetic relationship of biomarkers associated with OCD and control groups through the Linear discriminant Effect Size (LEfSe) analysis (α value=0.05, logarithmic LDA score threshold=2.0) in oropharyngeal samples.